Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to $3.4 million.

  • Marker Therapeutics' Operating Expenses fell 2210.48% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 2547.85%. This contributed to the annual value of $17.7 million for FY2024, which is 102.31% down from last year.
  • According to the latest figures from Q3 2025, Marker Therapeutics' Operating Expenses is $3.4 million, which was down 2210.48% from $5.1 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Operating Expenses peaked at $10.8 million during Q1 2022, and registered a low of $3.4 million during Q3 2025.
  • In the last 4 years, Marker Therapeutics' Operating Expenses had a median value of $4.9 million in 2023 and averaged $5.1 million.
  • As far as peak fluctuations go, Marker Therapeutics' Operating Expenses crashed by 4934.61% in 2023, and later soared by 5304.67% in 2024.
  • Marker Therapeutics' Operating Expenses (Quarter) stood at $3.8 million in 2022, then grew by 5.17% to $4.0 million in 2023, then surged by 53.05% to $6.1 million in 2024, then crashed by 44.88% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $5.1 million for Q2 2025, and $5.0 million during Q1 2025.